Key points from article :
Biogelx, a life sciences spin-out from the University of Strathclyde, has appointed Mitch Scanlan as its new chief executive. Scanlan takes over from founder David Lightbody, who stepped down to focus on commercialising the company’s innovative 3D biomaterial technology. Biogelx, based at BioCity Scotland, develops synthetic hydrogel platforms that support advanced 3D cell culture applications such as bioprinting, tissue engineering, and regenerative medicine.
Scanlan brings a wealth of experience from the life sciences industry, having worked for major companies like Sartorius Stedim Biotech, Merck Millipore, and BioOutsource—a Glasgow-based firm he helped grow significantly before it was acquired by Sartorius. He emphasized the potential of Biogelx’s technology to become an essential component for various high-growth biotech applications and highlighted the company’s intent to both expand its existing product line and form new commercial partnerships.
The appointment has been welcomed by BioCity Scotland, with managing director Toby Reid praising Scanlan’s strong commercial background and its importance for advancing the company’s growth. This leadership change marks an exciting phase for Biogelx as it looks to further develop and commercialize its cutting-edge biomaterials.
